Home › Trial NCT03929965
Anlotinib in Advanced Solid Tumors With FGFR Alteration
- Trial IDNCT03929965
- StatusUnknown
- PhaseN/A
- Study typeInterventional
- SponsorShanghai Changzheng Hospital
- Enrollment30
- Start date2019-07-01
- ConditionsAdvanced Solid Tumor
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.